Brief: Echoiq Enters Commercial Licensing Agreement With Respiri
25/01/2024 01:07
Jan 25 (Reuters) - EchoIQ Ltd EIQ.AX :
* ENTERED INTO A COMMERCIAL LICENSING AGREEMENT WITH RESPIRI
* AGREEMENT TO APPLY CO'S AI-BACKED ECHOSOLVTM
CARDIOVASCULAR
DECISION SUPPORT TO RESPIRI'S REMOTE PATIENT MONITORING USER
BASE
Source text for Eikon: ID:nASX5rK1Y5
Further company coverage: EIQ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on EchoIQ
See all newsAustralia's EchoIQ gains most in nearly 3 months after FDA update
Brief: EchoIQ Says FDA Raises No Concerns About Echosolv HF Technology Or Core Functionality
Australia's EchoIQ heads for worst week in seven years after US FDA setback
Australia's Echo IQ logs worst day in seven years after FDA setback
Brief: EchoIQ Requests Trading Halt